Seamless Therapeutics, a startup developing a new form of gene editing based on enzymes called recombinases, has struck a partnership with Eli Lilly that could be worth more than $1.12 billion, the company announced Wednesday …
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new


